Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
Location: United States, New York
Member count: 51-200
Total raised: $128.15M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 22.05.2021 | Series B | $67.4M | - | finsmes.co... |
| 11.02.2019 | Series A | $60.75M | - | vcnewsdail... |
Mentions in press and media 9
| Date | Title | Description | Category | Author | Source |
| 22.05.2021 | HiberCell ... | HiberCell, a NYC-based biotech... | USA | - | finsmes.co... |
| 19.05.2021 | HiberCell ... | Proceeds to advance pipeline o... | - | - | marketscre... |
| 21.01.2021 | HiberCell ... | NEW YORK, Jan. 21, 2021 /PRN... | - | - | prnewswire... |
| 02.12.2020 | HiberCell ... | NEW YORK, Dec. 2, 2020 /PRNe... | - | - | prnewswire... |
| 07.02.2019 | HiberCell ... | HiberCell, a New York City-bas... | USA | - | finsmes.co... |
| 07.02.2019 | Startup Hi... | The company’s pipeline page li... | - | - | medcitynew... |
| 07.02.2019 | HiberCell ... | NEW YORK, NY, HiberCell laun... | - | - | vcnewsdail... |
| 07.02.2019 | HiberCell ... | HiberCell, a biotechnology com... | - | - | citybizlis... |
| - | Startup Hi... | Researchers at New York’s Moun... | - | - | medcitynew... |